Enhabit, Inc.

As of August 9, 2023, Enhabit, Inc. is considered overvalued with a P/E ratio of 22 and an EV to EBITDA of 12.62, underperforming the S&P 500 with a year-to-date return of 3.2% compared to the S&P's 12.22%.

As of August 9, 2023, Enhabit, Inc. is considered overvalued and risky due to its high P/E ratio of 22 compared to the peer average of 19.25, low returns on capital, and a significant decline in stock performance over three years.

As of June 20, 2025, Enhabit, Inc. shows a mildly bullish trend, supported by weekly MACD and Bollinger Bands, despite mixed signals from the daily moving averages and bearish indications from the weekly KST and Dow Theory.

Enhabit, Inc. is a micro-cap company in the Pharmaceuticals & Biotechnology industry, with recent net sales of $260 million and a net profit of $18 million. It has a market cap of $485.11 million and key metrics include a P/E ratio of 22.00 and a debt equity ratio of 0.84.

As of Jun 18, Enhabit, Inc. has a market capitalization of 485.11 million, with net sales of 1,032.30 million and a net profit of -136.50 million over the latest four quarters. The company reported shareholder's funds of 523.50 million and total assets of 1,252.20 million as of Dec 24.